Osteoarthritis and Bone Disorders News

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

The FDA cleared a wearable vibration belt device as a non-pharmacologic treatment for postmenopausal women with osteopenia, according to an industry press release.

Machine learning algorithms can be effective in predicting osteoporosis among patients with rheumatoid arthritis, as well as identifying new predictive factors, according to data published in Nature Scientific Reports.

Patients with cirrhosis are less frequently screened for osteoporosis compared with the general population, and less than 25% with low bone density actually receive treatment, according to research in Alimentary Pharmacology & Therapeutics.

SAN DIEGO — Patients with diabetes mellitus who undergo total hip arthroplasty demonstrate an increased risk for health care use, including increased length of stay, and acute renal failure, according to a speaker at ACR Convergence 2023.

SAN DIEGO — Patients with acute calcium pyrophosphate crystal arthritis demonstrate double the risk for fractures vs. matched comparators, according to data presented at ACR Convergence 2023.

The identification of rare genetic variants that influence bone mineral density did not significantly improve fracture risk screening among a large group of adults, according to data published in Journal of Bone and Mineral Research.

SAN DIEGO — Romosozumab is superior to denosumab for increasing bone mineral density in the spine at 12 months among chronic glucocorticoid users with osteoporosis at high fracture risk, according to data presented at ACR Convergence 2023.

SAN DIEGO — A single injection of TLC599, a liposomal formulation of dexamethasone sodium phosphate, bested placebo for osteoarthritis knee pain over 24 weeks, while a second injection extended benefits to week 52, according to data.